Printed on 6/29/2026
For informational purposes only. This is not medical advice.
The Recurrence Of Kidney Stone (ROKS) nomogram predicts the risk of a second symptomatic kidney stone episode based on patient demographics, BMI, stone history, family history, and stone composition. It helps guide preventive counseling and metabolic workup intensity. Calculate BMI input with [BMI Calculator](/tools/bmi-calculator). For acute presentation assessment, see [STONE Score Calculator](/tools/stone-score). Monitor renal function for CKD from recurrent stones with [eGFR Calculator](/tools/egfr-calculator) and [Creatinine Clearance](/tools/creatinine-clearance).
Formula: Simplified ROKS model incorporating sex, age, BMI, stone history, family history, and composition.
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
Record age, sex, BMI (calculate with [BMI Calculator](/tools/bmi-calculator)), number of prior stone episodes, family history of kidney stones, and stone composition if known from stone analysis. First-time stone formers with unknown composition still receive a risk estimate.
The ROKS model applies weighted regression coefficients to each variable. Risk-amplifying factors include male sex, younger age at first stone, elevated BMI, multiple prior episodes, family history, and certain compositions (uric acid, calcium phosphate/brushite, struvite).
Low risk (under 15% at 5 years): increase fluid intake to >2.5 L/day. Moderate risk (15–30%): add dietary counseling and 24-hour urine metabolic evaluation. High risk (above 30%): comprehensive metabolic workup plus pharmacologic prevention (thiazides, potassium citrate, or allopurinol based on metabolic profile).
Urologists, nephrologists
Discuss recurrence risk immediately after a stone event when patients are most motivated to make lifestyle changes. High-risk patients are most likely to benefit from intensive dietary counseling, 24-hour urine evaluation, and preventive pharmacotherapy. Use ROKS to justify the intensity of follow-up.
Nephrologists, urologists
Metabolic evaluation with 24-hour urine collection is time-consuming and costly. ROKS stratifies which patients benefit most from this workup. Most guidelines recommend metabolic evaluation for all recurrent stone formers; ROKS helps justify evaluation for high-risk first-time formers as well.
Urologists, nephrologists
Thiazide diuretics, potassium citrate, and allopurinol are effective for specific stone metabolic abnormalities but have side effects. A high ROKS risk score, combined with 24-hour urine abnormalities, provides the evidence base for prescribing preventive pharmacotherapy.
Primary care physicians, nephrologists
Concrete recurrence probability numbers motivate patient behavior change more effectively than general advice. Telling a patient they have a 42% chance of another stone in 5 years is more actionable than 'kidney stones tend to recur.' High-risk patients are more adherent to fluid intake goals.
Urologists, radiologists
ROKS risk guides imaging surveillance frequency. High-risk patients (particularly struvite and calcium phosphate stone formers) benefit from more frequent renal imaging (annual ultrasound or low-dose CT) to detect new stone formation before symptomatic events. Monitor renal function with [eGFR Calculator](/tools/egfr-calculator).
Increasing urine output to at least 2.5 liters per day (targeting urine that is pale yellow, not clear) is the most evidence-based intervention for kidney stone prevention regardless of stone type. The Curhan epidemiologic studies showed a 30–40% reduction in stone recurrence with high fluid intake across all dietary patterns.
Counter-intuitively, low-calcium diets increase oxalate absorption from the gut (calcium normally binds dietary oxalate in the intestine). Calcium stone formers should maintain 1000–1200 mg/day dietary calcium (not supplements) to reduce urinary oxalate. This finding from the DASH diet trials is frequently overlooked in general medical practice.
Uric acid stones are radiolucent (invisible on plain X-ray) and uniquely dissolvable with oral potassium citrate, which alkalizes the urine to pH 6.5–7.0. High ROKS risk with uric acid composition should trigger urgent evaluation for gout, high-purine diet, and urinary pH management — no procedure needed if treated pharmacologically.
Struvite stones (from urease-producing bacteria) have the highest recurrence risk. Complete surgical stone removal combined with targeted antibiotic therapy based on culture is required. Medical prevention alone is insufficient — residual stone fragments serve as a nidus for new stone formation and persistent infection.
The 24-hour urine test measures urinary calcium, oxalate, uric acid, citrate, sodium, and pH. Identifying the specific abnormality (e.g., hypercalciuria → thiazide; hypocitraturia → potassium citrate; hyperuricosuria → allopurinol) allows targeted pharmacologic prevention. Empiric treatment without metabolic data is significantly less effective.
The ROKS (Recurrence Of Kidney Stones) nomogram was developed by Burgess et al. (2023) from a Dutch prospective cohort and externally validated in independent populations. Curhan et al. (NEJM 1993, HPFS cohort) established the epidemiologic foundation for dietary risk factors. AUA Stone Guidelines (2019) and EAU Urolithiasis Guidelines (2023) provide the evidence base for metabolic evaluation and prevention protocols.
Your ROKS nomogram result estimates the probability of experiencing a second symptomatic kidney stone episode at 2 and 5 years after your first stone. A low recurrence risk (under 15% at 5 years) suggests that standard preventive measures such as increased fluid intake may be sufficient. A moderate risk (15-30% at 5 years) indicates that dietary counseling and a 24-hour urine metabolic evaluation should be considered. A high risk (over 30% at 5 years) strongly supports comprehensive metabolic workup and often pharmacologic prevention.
Key risk-amplifying factors include male sex, younger age at first stone episode, elevated BMI, family history, multiple prior episodes, and certain stone compositions such as uric acid and calcium phosphate/brushite stones. The result should be discussed with your urologist to develop a personalized prevention strategy.
Use the ROKS nomogram after a patient has experienced their first symptomatic kidney stone episode and stone analysis or imaging has been completed. It is most valuable in the outpatient urology or nephrology clinic setting when deciding how aggressively to pursue metabolic workup and preventive therapy.
The tool is particularly helpful for shared decision-making with patients who want to understand their personal recurrence risk. It can motivate adherence to fluid intake goals and dietary modifications in higher-risk patients, and it helps clinicians triage who would benefit most from 24-hour urine collection, pharmacologic therapy (thiazides, potassium citrate, or allopurinol), and more frequent follow-up imaging.
The ROKS nomogram was developed and validated primarily in a Dutch population, which may limit its generalizability to other ethnic or geographic populations with different dietary patterns and genetic predispositions. The model does not incorporate detailed metabolic data from 24-hour urine studies (such as hypercalciuria, hyperoxaluria, or hypocitraturia), which are important independent predictors of recurrence.
Additionally, the nomogram does not account for anatomic factors such as medullary sponge kidney, horseshoe kidney, or ureteral stricture, all of which independently increase stone recurrence risk. Dietary habits, hydration status, and medication use (e.g., topiramate, calcium supplements) are also not captured. The tool provides a population-level probability and should be interpreted alongside individual metabolic and anatomic evaluation.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Calculate the STONE score to predict kidney stones in ED patients with flank pain. High score ≥10: 88.6% probability. Moderate 5–9: 51.3%. Low ≤4: 9.2%. Guides CT imaging decisions.
OpenClinicalCalculate eGFR with the CKD-EPI 2021 race-free formula to estimate kidney function and CKD stage from serum creatinine, age, and sex.
OpenClinicalCalculate creatinine clearance (CrCl) with Cockcroft-Gault to guide renal medication dose adjustments from age, weight, sex, and serum creatinine.
Open